How should erythema in the gastric antrum be evaluated and managed?

Evaluation and Management of Erythema in the Gastric Antrum

Erythema in the gastric antrum is a nonspecific endoscopic finding with poor predictive value for underlying pathology, and the diagnosis of gastritis or H. pylori infection must be confirmed by histopathology using systematic biopsy protocols rather than relying on visual appearance alone. 1, 2

Understanding the Limited Diagnostic Value of Erythema

Endoscopic erythema in the antrum has very limited diagnostic utility:

• Erythema shows poor correlation with histological gastritis, with sensitivity for detecting moderate to severe chronic inflammation not exceeding 56% in population studies 2
• No endoscopic features, including erythema, demonstrate sensitivity greater than 57% for H. pylori infection when evaluated against histological confirmation 2
• Interobserver reliability for mucosal erythema is poor, ranging from only 62-74% agreement between experienced endoscopists 3
• The positive predictive value of erythema for histologically confirmed gastritis rarely exceeds 50% 3

Mandatory Biopsy Protocol for Antral Erythema

When erythema is present in the gastric antrum, systematic biopsies must be obtained regardless of the endoscopic appearance to establish the correct diagnosis:

Standard Biopsy Protocol for Dyspepsia/H. pylori Detection

Obtain 5 biopsy specimens using the Sydney System protocol 1:

• Two from the antrum (greater and lesser curve, within 2-3 cm from pylorus)
• One from the incisura angularis
• Two from the gastric body (lesser curvature 4 cm proximal to angle; greater curvature 8 cm distal to cardia)

Place specimens in two separately labeled jars (body; antrum/incisura) to allow assessment of gastritis distribution 1

Critical Pre-Biopsy Considerations

• Stop proton pump inhibitors for 2 weeks before endoscopy if possible, as PPIs cause proximal migration of H. pylori from antrum to body and reduce bacterial load, leading to false-negative results 1
• If PPI discontinuation is not possible, validated IgG serology can be performed as it is unaffected by local gastric changes 1

Differential Diagnosis Based on Histopathology

Once biopsies are obtained, the histological findings will guide management:

H. pylori-Associated Gastritis

• H. pylori may be present despite normal-appearing stomach or nonspecific erythema 1
• Diagnosis requires histological confirmation, as approximately 5-10% of H. pylori infections occur with endoscopically normal mucosa 1
• If H. pylori is detected, eradication therapy should be administered with confirmation of successful eradication using non-serological testing at least 4 weeks after treatment completion 1, 4

Atrophic Gastritis with Intestinal Metaplasia

• Atrophic mucosa has a pale appearance with increased visibility of submucosal vessels and loss of gastric folds, not erythema 1
• However, intestinal metaplasia can present with nodular irregular mucosa, and mottled patchy erythema has been associated with intestinal metaplasia in post-eradication patients 5
• If atrophic gastritis or intestinal metaplasia is confirmed histologically, surveillance endoscopy every 3 years should be considered for advanced disease 1

Non-Atrophic Gastritis

• Antral-predominant, body-sparing non-atrophic gastritis is associated with high acid production and is the typical pattern in H. pylori-positive patients with dyspepsia 1
• Treatment focuses on H. pylori eradication if present, which provides long-term symptom relief in 1 of 12 patients with functional dyspepsia 1

Management Algorithm

Step 1: Obtain systematic biopsies using the 5-specimen Sydney protocol with separate jars for body and antrum 1

Step 2: Request histological evaluation for:

• H. pylori presence (H&E staining is sufficient; special stains only if chronic gastritis present without visible organisms) 1
• Degree and distribution of chronic inflammation
• Presence and extent of atrophy
• Presence and subtype of intestinal metaplasia 1

Step 3: Manage based on histological findings:

• If H. pylori positive: Initiate eradication therapy and confirm eradication ≥4 weeks post-treatment 4, 6
• If atrophic gastritis/intestinal metaplasia: Assess extent and severity for surveillance planning 1
• If non-specific gastritis without H. pylori: Consider empirical PPI therapy for symptom management 7

Common Pitfalls to Avoid

• Do not rely on endoscopic appearance alone to diagnose or exclude gastritis or H. pylori infection 2, 3
• Do not perform endoscopy while patient is on PPIs without recognizing the high false-negative rate for H. pylori detection 1
• Do not obtain biopsies only from the antrum in patients on acid suppression, as H. pylori migrates proximally to the body 1
• Do not use rapid urease test as the sole diagnostic method, as sensitivity is only 80-95% and false negatives occur with low bacterial density or recent medication use 7
• Do not assume erythema indicates active inflammation, as the correlation is poor and histological confirmation is required 2, 3